Stay Up to Date 
with the Latest

The science
moves fast
and so do
the stories.

ADDF Financing

Alzheimer’s disease: The Alzheimer’s Drug Discovery Foundation (ADDF) invests $4.2M in GliaPharm to advance its lead program

New collaboration


New hire at GliaPharm SA



Wyss center

Innosuisse support

GliaPharm receives support from Innosuisse for a project to develop specific cell therapy to treat neurological diseases in collaboration with Universities of Bern and Lausanne.

HEPIA collaboration

GliaPharm receives grant for collaboration with HEPIA to setup a new 3D culture method using brain organoids from mouse and human-derived cells.

European Congress of Neuropsychopharmacology

GliaPharm to present at the European Congress of Neuropsychopharmacology – Symposium on “Beyond the Neurocentric Paradigm: Targeting Astrocytes and Neuroglial Interactions in CNS Disorders”. September 13th 2020.

LifeSci Symposium

GliaPharm presented at the LifeSci Partners Summer Symposium on August 5th 2020


GliaPharm to present at the virtual #FOXG1ScienceSymposium on August 17/18. Register here to tune in to hear from all the researchers, industry and more about the path to a cure for #FOXG1. #FOXG1SS2020

CHF 2 Million financing

GliaPharm completes a CHF 2 Million financing to advance its drug development program for an orphan neurological disease